39 research outputs found
Data from the Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer by Bruchovsky et al (2006).
No full textThe data from the Phase II study by Bruchovsky et al on intermittent androgen deprivation therapy are publicly available at: http://www.nicholasbruchovsky.com/clinicalResearch.htmlThis figshare entry is purely for record keeping. We emphasize that we do not hold ownership of these data, and that all questions about their collection and use should be directed towards the original study team.Details on the study can be found in the following publications:- Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol. 2000 Fall;4(3):191-9;discussion 201. PMID: 11062374.- Bruchovsky, N., Klotz, L., Crook, J., Malone, S., Ludgate, C., Morris, W. J., Gleave, M. E., & Goldenberg, S. L. (2006). Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. Cancer, 107(2), 389–395. https://doi.org/10.1002/cncr.21989- Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007 Mar 1;109(5):858-67. doi: 10.1002/cncr.22464. PMID: 17265527.</div
Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer
No full textAbstract:
We propose a method for achieving an optimal protocol of intermittent androgen suppression for the treatment of prostate cancer. Since the model that reproduces the dynamical behavior of the surrogate tumor marker, prostate specific antigen, is piecewise linear, we can obtain an analytical solution for the model. Based on this, we derive conditions for either stopping or delaying recurrent disease. The solution also provides a design principle for the most favorable schedule of treatment that minimizes the rate of expansion of the malignant cell populatio
Hormones and cancer: new insights, new challenges
No full textAbstract not availableWayne D. Tilley, Christine L. Clarke, Stephen N. Birrell and Nicholas Bruchovsk
Basis for the Use of Drug and Hormone Combinations in the Treatment of Endocrine-Related Cancer
No full text
Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer
No full textProstate cancer is one of the most common malignant neoplasms in men with an overall incidence of approximately 15 per cent during the normal life span. Androgen-deprivation therapy (hormone therapy) is an effective treatment of this disease when progressed to an advanced stage. Despite impressive responses, such treatment when applied on a continuous basis is not curative and eventually culminates in androgen-independent disease. On the other hand, intermittent androgen suppression (IAS) was first conceived as a potential way of delaying progression to androgen-independence, in addition offering the possibility of reducing adverse effects and improving the quality of life. Although the validity of this approach has been confirmed in several clinical studies, the optimal scheduling of the cycles of on- and off-treatment remains to be explored. In the present article, we show that IAS lends itself to mathematical modelling with hybrid dynamical systems and that the model we have developed can be used to select the best strategy for keeping prostate cancer in an androgen-dependent state as long as possible. Our results also suggest that the current way of using IAS exceeds what is necessary for optimal control; in fact, we have found that to achieve optimal control, the amount of therapy (dose and duration of drugs) can be reduced by a factor of one half.</jats:p
Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways
No full text
